

Special Issue

Novel Combination Therapies for Acute Leukemia

Message from the Guest Editors

Over the last ten years, a great number of molecular aberrations have been identified in either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), making these disease optimal candidates for the development of investigational drugs targeting driver genetic mutations. It is now evident that most of these abnormalities could trigger the development of acute leukemia or have an important role in the pathogenesis and/or clonal expansion of leukemia. The routine application of novel molecular biology technologies has facilitated the development of such genetic lesions, with relevant clinical and therapeutical application. Furthermore, an increasing number of clinical trials have been testing “druggable” mutations in the context of novel targeted therapies, making this area more and more interesting in several areas of investigations. This Special Issue focuses on novel therapeutical approaches in acute leukemias and related diseases, and aims to collect original papers and commentaries in several areas of investigations concerning AML and ALL, including preclinical, clinical, and biological studies.

Guest Editors

Prof. Dr. Francesco Lanza

1. UO Ematologia, Ospedale S. Maria delle Croci, Via Randi 5, 48121 Ravenna, Italy

2. Department of Medicine and Surgery (DIMEC), University of Bologna, 40126 Bologna, Italy

Prof. Dr. Attilio Olivieri

Stem Cell Transplant Unit, Hematology Department, DISCLIMO-Università Politecnica delle Marche, 60126 Ancona, Italy

Deadline for manuscript submissions

closed (15 September 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/172289

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)